Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients ...

Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

The NHS will offer a once-daily triple therapy for cystic fibrosis to hundreds more patients, including those with rare ...

Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis transmembrane ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

ALYFTREK. There are no available safety data for ALYFTREK in patients who previously discontinued or interrupted treatment with drugs containing ELX, TEZ, or IVA due to adverse reactions.

ALYFTREK is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B) and should only be considered when there is a clear medical need, and benefit outweighs risk.